The Methodist Hospital Research Institute
337
68
108
136
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.6%
56 terminated/withdrawn out of 337 trials
70.8%
-15.8% vs industry average
6%
20 trials in Phase 3/4
45%
61 of 136 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (337)
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Role: collaborator
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
Role: collaborator
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Role: collaborator
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Role: collaborator
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Role: collaborator
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Role: collaborator
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Role: collaborator
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
Role: collaborator
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Role: collaborator
Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
Role: collaborator
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
Role: collaborator
Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer
Role: lead
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
Role: lead
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
Role: collaborator
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
Role: collaborator
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Role: lead
Personalized Transcranial Direct Current Stimulation in Stroke Recovery
Role: lead
CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
Role: collaborator
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Role: collaborator
T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
Role: collaborator